Thursday, July 3, 2025 7/3/2025

DEVELOPMENT OF A NEXT GENERATION ANTHRAX VACCINE, DMPA7909

Award Number: U01AI082224
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: COOPERATIVE AGREEMENT
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/30/2009
PERIOD OF PERFORMANCE END DATE: 08/31/2011

Group Awards By:

View Award Description

DEVELOPMENT OF A NEXT GENERATION ANTHRAX VACCINE, DMPA7909 - DESCRIPTION (provided by applicant): Emergent BioSolutions Inc. (Emergent) is proposing to advance the development of a novel anthrax vaccine dmPA7909. This next generation vaccine is composed of the double-mutant recombinant Bacillus anthracis protective antigen (dmPA), the aluminum adjuvant Alhydrogel(r) and the immunostimulatory oligodeoxynucleotide compound CPG 7909 (Vaxlmmune(tm)) formulated as a dry powder. To ensure that the dmPA7909 vaccine will be stable even at elevated temperatures, Emergent employed proven stabilizing technologies for each of the components in the vaccine formulation. The dmPA has been genetically engineered to remove two major protease cleavage sites within the molecule, and as a result, its stability is significantly improved. This stable dmPA adsorbed to Alhydrogel has been tested in animal efficacy studies and is currently being used in combination with Alhydrogel in a Phase 1 clinical trial. Alhydrogel (aluminum hydroxide) has a long history of use in vaccines including childhood vaccines and has documented stability at 25 and 37 ¿C. CPG 7909, unlike other CpG oligonucleotides, has all of its phosphate linkages replaced with phosphorothioate bonds, thus decreasing its sensitivity to nucleases, thus rendering it stable. Additionally, the spray-dried powder formulation dramatically enhances vaccine stability even at extreme temperatures for an extended period of time. CPG 7909 has also been extensively tested in the clinic alone, and in combination with other Alhydrogel-adjuvanted recombinant vaccines. The characteristics of dmPA7909 that make it an ideal candidate to meet the nation's needs for a next generation anthrax vaccine are: 1. Rapid immune response following 2-3 doses 2. Long-term stability to facilitate ambient temperature storage in the Strategic National Stockpile 3. Ability to be administered in a national emergency without the need for special storage conditions


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2010 ( Subtotal = $2,896,688 )
2010	2010	EMERGENT IMMUNOSOLUTIONS INC/BIOPORT CORP	300 PROFESSIONAL DRIVE	GAITHERSBURG	MD	20879	MONTGOMERY	USA	Trans-NIH Recovery Act Research Support	001	2	9/15/2010	NON-COMPETING CONTINUATION	$2,481,738
2010	2010	EMERGENT IMMUNOSOLUTIONS INC/BIOPORT CORP	300 PROFESSIONAL DRIVE	GAITHERSBURG	MD	20879	MONTGOMERY	USA	Trans-NIH Recovery Act Research Support	002	2	9/29/2010	NON-COMPETING CONTINUATION	$414,950
2010	2009	EMERGENT IMMUNOSOLUTIONS INC/BIOPORT CORP	300 PROFESSIONAL DRIVE	GAITHERSBURG	MD	20879	MONTGOMERY	USA	Trans-NIH Recovery Act Research Support	000	1	9/14/2010	NEW	$0
														Subtotal = $2,896,688

Issue Date FY: 2009 ( Subtotal = $2,454,564 )
2009	2009	EMERGENT IMMUNOSOLUTIONS INC/BIOPORT CORP	300 PROFESSIONAL DRIVE	GAITHERSBURG	MD	20879	MONTGOMERY	USA	Trans-NIH Recovery Act Research Support	000	1	9/22/2009	NEW	$2,454,564
														Subtotal = $2,454,564

Grand Total All Awards = $5,351,252

Top

All Categories

About

Search

Reports

Data Submission

Award Information

DEVELOPMENT OF A NEXT GENERATION ANTHRAX VACCINE, DMPA7909

Award Number: U01AI082224

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: COOPERATIVE AGREEMENT

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/30/2009

PERIOD OF PERFORMANCE END DATE: 08/31/2011

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer